Zacks Research Has Negative Outlook of BDX FY2027 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research lowered their FY2027 earnings estimates for shares of Becton, Dickinson and Company in a report released on Monday, December 16th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings of $16.68 per share for the year, down from their prior estimate of $16.75. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.42 EPS.

A number of other equities analysts also recently issued reports on BDX. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $283.50.

Becton, Dickinson and Company Stock Down 0.7 %

Shares of Becton, Dickinson and Company stock opened at $224.09 on Wednesday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $230.29 and its 200 day moving average is $233.34. The company has a market cap of $64.79 billion, a price-to-earnings ratio of 37.73, a price-to-earnings-growth ratio of 1.64 and a beta of 0.41.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently modified their holdings of the business. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in Becton, Dickinson and Company in the third quarter worth approximately $33,000. Tompkins Financial Corp grew its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC raised its position in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Finally, Abound Wealth Management raised its position in Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.86%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.